MINOCET 125 mg/5 ml Price

Overview

Welcome to Dwaey, specifically on MINOCET 125 mg/5 ml Powder for Oral Suspension page.
This medicine contains an important and useful components, as it consists of Cefdinir.
MINOCET 125 mg/5 ml is available in the market in concentration 125 mg/5 ml and in the form of Powder for Oral Suspension.

TABUK PHARMACEUTICAL MANUFACTURING CO. is the producer of MINOCET 125 mg/5 ml and it is imported from SAUDI ARABIA, The most popular alternatives of MINOCET 125 mg/5 ml are listed downward .

Mode Of Action

Cefdinir binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.

Indication

• Community-acquired pneumonia
• Susceptible infections
• Sinusitis
• Otitis media
• Sore throat
• Soft tissue infections
• Respiratory tract infections
• Acute Exacerbations of Chronic bronchitis
• Acute Maxillary Sinusitis

Precaution

Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency. Lactation: Unknown whether drug is excreted in milk

Side Effects

• >10% Diarrhea (8-15%) 1-10% Vaginal moniliasis (<4%)
• Nausea (3%)
• Rash (3%)
• Headache (2%)
• Increased urine leukocytes (2%)
• Increased urine protein (1-2%)
• Decreased lymphocytes (1%)
• Glycosuria (1%)
• Increased alkaline phosphatase (1%)
• Increased eosinophils (1%)
• Increased platelets (1%) Potentially Fatal: Anaphylaxis; renal and hepatic failure.

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.